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SUMMARY
The obligate intracellular bacterial pathogen Chlamydia trachomatis injects numerous effector
proteins into the epithelial cell cytoplasm to manipulate host functions important for bacterial
survival. In addition, the bacterium secretes a serine protease, chlamydial protease-like activity
factor (CPAF). Although several CPAF targets are reported, the significance of CPAF-mediated
proteolysis is unclear due to the lack of specific CPAF inhibitors and the diversity of host targets.
We report that CPAF also targets chlamydial effectors secreted early during the establishment of
the pathogen-containing vacuole (“inclusion”). We designed a cell-permeable CPAF-specific
inhibitory peptide and used it to determine that CPAF prevents superinfection by degrading early
Chlamydia effectors translocated during entry into a pre-infected cell. Prolonged CPAF inhibition
leads to loss of inclusion integrity and caspase-1-dependent death of infected epithelial cells. Thus,
CPAF functions in niche protection, inclusion integrity and pathogen survival, making the
development of CPAF-specific protease inhibitors an attractive anti-chlamydial therapeutic
strategy.
INTRODUCTION
The obligate intracellular bacterial pathogen Chlamydia trachomatis primarily infects
epithelial cells of the urogenital tract and the conjunctiva (Adderley-Kelly and Stephens,
2005) that can lead to severe complications such as pelvic inflammatory disease, ectopic
pregnancy and infertility. Similarly, ocular infections can lead to trachoma, the leading
cause of infectious blindness worldwide (Hu, 2010). Infection is initiated by attachment and
entry of elementary bodies (EB), the infectious form of Chlamydia, into epithelial cells.
Upon entry, EBs transition into replicative reticulate bodies (RB) and establish a
parasitophorous vacuole (“inclusion”) that prevents fusion with lysosomal compartments. At
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mid- to late stages of infection, RBs revert back to EBs, and are released to infect
neighboring cells (Belland et al., 2003).
C. trachomatis employs a type III secretion (T3S) system to translocate virulence proteins
directly into the cytoplasm of the host cell. These effector proteins mediate cell invasion,
rerouting of membrane transport, and manipulation of signaling pathways that are important
in immunity (Valdivia, 2008). More than 5% of Chlamydia’s genome is predicted to encode
T3S effector proteins (Arnold et al., 2009), including a family of inclusion membrane
proteins (Incs) that reside at the interface of the host cytoplasm and inclusion membrane
(Scidmore-Carlson et al., 1999). These proteins are implicated in the modulation of various
host cellular functions, including membrane transport, apoptosis and microtubule dynamics
(Betts et al., 2009). Unfortunately, because of Chlamydia’s obligate intracellular lifestyle
and lack of tools for genetic manipulation, most putative chlamydial effectors remain poorly
characterized.
In addition to T3S effectors, proteins that use the general secretion pathway can access the
host cell cytoplasm to manipulate host cellular processes (Chen et al., 2010). A prominent
example is the chlamydial protease-like activity factor (CPAF), a serine protease that is first
secreted into the inclusion lumen and eventually crosses the inclusion membrane (Zhong et
al., 2001). CPAF cleaves transcription factors (RFX5 and USF1) required for the expression
of antigen presentation molecules (MHC) (Zhong et al., 2001), the pro-apoptotic factors Bim
and Puma (Pirbhai et al., 2006; Zhong et al., 2001) and p65/RelA, a transcription factor
required for NF-κB signaling (Christian et al., 2010). Recently, there has been an expanding
list of identified CPAF targets, underscoring the multiple roles played by this protease in the
biology of Chlamydia infections. CPAF cleaves the adherence junction protein nectin1 (Sun
et al., 2008), the MHC-like protein CD1d (Kawana et al., 2007), the pro-inflammatory
protein HMGB1 (Yu et al., 2010), the mitotic cell cycle regulator Cyclin B, and PARP – a
mediator of DNA-damage during apoptosis (Paschen et al., 2008). CPAF also remodels
intermediate filaments (Dong et al., 2004; Kumar and Valdivia, 2008) that circumscribe the
inclusion to maintain its integrity and limit the exposure of inclusion contents to cytoplasmic
microbial pattern recognition receptors (Kumar and Valdivia, 2008).
Recent observations with an inducible CPAF over-expression system suggested that this
protease can initiate a host cell death pathway that mimics the necrotic cell death observed at
the end of the chlamydial life cycle (Paschen et al., 2008) and thus contribute to acute
inflammation and tissue scarring. Yet the significance of CPAF-mediated proteolysis during
infection is unclear due to the lack of specific CPAF inhibitors and the large number and
variability in host cell targets. Nonetheless, the abundance of specific targets implies that
CPAF-mediated proteolysis represents a core strategy employed by Chlamydia to modify
host-signaling pathways and usurp the cellular machinery for its own benefit.
Here we report that in addition to targeting host proteins, CPAF cleaves bacterial effectors
translocated during invasion and early in inclusion biogenesis. We demonstrate that CPAF is
essential for bacterial replication, maintaining inclusion structural integrity and evasion of
caspase-1-dependent cell death in epithelial cells. These results establish CPAF as a
virulence factor required for Chlamydia survival within infected cells and reveal unexpected
roles for this protease in regulating T3S effectors after their translocation into the host cell
and in maintaining host cell viability.
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A subset of Chlamydia effector proteins is sensitive to proteolysis
Approximately 10% of the Chlamydia genome encodes proteins that potentially access the
cytoplasm of the infected host cell and act as effectors (Arnold et al., 2009) (Saka and
Valdivia, unpublished). Because effectors are secreted at distinct stages during infection, we
hypothesized that their activity in the host cytoplasm is regulated as inappropriate activity of
effectors might negatively impact bacterial growth. Since proteolysis is a common
mechanism of post-translational control, we tested a panel of 309 recombinant Chlamydia-
specific proteins, including known and potential effector proteins, for sensitivity to
proteolysis following incubation with lysates from infected and uninfected HeLa cells
(Figure S1). Thirty of the expressed chlamydial proteins were sensitive to cytosols derived
from infected cells (Figure S1A). Protein processing ranged from the generation of distinct
cleavage fragments to complete degradation (Figure S1B). The protease-sensitive
chlamydial proteins comprised inclusion membrane proteins (n=11), outer membrane
proteins (n=3), proteases (n=2) and ORFs of unknown function (n=14) (Figure S1C and
Table S2). Thirteen of the thirty were also sensitive to proteolysis when treated with lysates
from uninfected cells, indicating that these proteins are likely targets of host proteases
(Figure 1A, Figure S1C–D and Table S2).
The secreted protease CPAF cleaves a subset of effector proteins
Cleavage of nine chlamydial proteins by was inhibited by pre-treatment of infected HeLa
cytosols with lactacystin but not the unrelated proteosomal inhibitors MG132 and ALLN
(Figure S1D and data not shown). Because this inhibitor sensitivity profile is shared by
CPAF (Pirbhai et al., 2006; Zhong et al., 2000) we tested if CPAF played a role in these
cleavage events by treating cytosols from infected HeLa cells with anti-CPAF antisera. Anti-
CPAF antisera, but not control antisera, blocked the degradation of recombinant bacterial
proteins (Figure S2A). In this manner we determined that all proteolysis-sensitive
Chlamydia proteins were likely substrates of CPAF (Figure 1A). We then tested if CPAF
was sufficient for these cleavage events. Recombinant CPAF readily cleaved vimentin, a
well-characterized CPAF substrate (Kumar and Valdivia, 2008; Paschen et al., 2008) and
GST-tagged chlamydial proteins Ct005, IncD (Ct115), IncE (Ct116), IncC (Ct233), Ct288,
CT694, CT695, Ct813 and TARP (Ct456) (Figure 1B). In contrast, GST-tagged proteins that
were identified as (1) not sensitive to proteolysis, (2) sensitive to a non-CPAF chlamydial
protease or (3) sensitive to a host protease were not cleaved by recombinant CPAF (Figure
S1D, S2B, and data not shown). Like endogenous CPAF, proteolysis by recombinant CPAF
was inhibited by lactacystin but not by MG132, ALLN, or a range of serine protease
inhibitors (Figure 1B and FigureS2C). The proteins identified as potential CPAF substrates
all contain putative T3S signals (Arnold et al., 2009), and fall into two main categories: (1)
experimentally validated effectors that are pre-packed into EBs (Clifton et al., 2004; Hower
et al., 2009) and (2) inclusion membrane proteins whose mRNAs are expressed early (1–3 h)
after invasion (Belland et al., 2003) (Figure 1C).
We next addressed whether the chlamydial CPAF substrates were cleaved during infection.
First, we expressed the EGFP-tagged CPAF substrates Ct005 and IncD in HeLa cells and
determined that these proteins were processed only upon Chlamydia infection (Figure S2D).
We generated antibodies against three of these proteins (Ct005, IncC and IncD) and
confirmed by immunofluorescence microscopy (IF) that they are expressed by 6 h post-
infection (Figure S2E). Because CPAF is not expressed until later in infection (>18 h), we
predicted that if Ct005, IncC and IncD were CPAF substrates their abundance would
decrease with the onset of CPAF secretion. We assessed protein abundance semi-
quantitatively by immunoblot analysis of membranes isolated from Chlamydia-infected
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HeLa cells. The levels of major outer membrane protein (MOMP) and the inclusion
membrane protein IncG, which are not CPAF substrates, increased throughout infection,
reflecting the increased bacterial loads in these cells. In contrast, the levels of Ct005, IncC
and IncD increased from 24–36 h but dropped at 48 h (Figure 1D). Overall, these
experiments suggest an inverse correlation between the onset of CPAF expression and the
abundance of these three secreted chlamydial proteins. Consistent with their potential as
bona fide CPAF targets, endogenous Ct005, IncC and IncD from isolated membranes of
Chlamydia-infected cells (24 hpi) were efficiently cleaved by recombinant CPAF in vitro
(Figure S2F).
CPAF cleaves Tarp during Chlamydia entry into pre-infected cells
We identified the EB proteins Tarp and Ct694 as potential substrates of CPAF-mediated
degradation (Figure 1B–C). Tarp and CT694 are pre-packaged into EBs and translocated
into the host cell during chlamydial invasion (Clifton et al., 2004; Hower et al., 2009).
Recombinant CPAF specifically degraded Tarp and Ct694 from EB lysates, but not
housekeeping proteins, and its incubation with lysates did not result in the non-specific
degradation of EB proteins (Figure S2G–H).
One scenario where Tarp and Ct694 would encounter CPAF would be when an EB infects a
cell that already contains a mature inclusion. We predicted that under these conditions Tarp
translocated by EBs would be rapidly degraded. To test this, we first compared the levels of
Tarp at EB attachment sites on uninfected versus pre-infected HeLa cells. Tarp is
phosphorylated at multiple tyrosine residues by host tyrosine kinases (Jewett et al., 2008;
Mehlitz et al., 2008) and IF staining with anti-phosphotyrosine antibodies reveals a
prominent cup of immunoreactive material at EB attachments sites (Clifton et al., 2004). We
observed multiple phosphotyrosine-positive foci immediately adjacent to EBs intimately
attached to the plasma membrane of HeLa cells. These foci, however, are largely absent at
EB attachment sites in HeLa cells that were pre-infected for 30 h (Figure 2A–B), indicating
that Tarp translocation or phosphorylation is inhibited or that translocated Tarp is degraded.
To determine the stability of translocated Tarp under these infection conditions, we infected
HeLa cells or inclusion-containing HeLa cells (30 hpi) with 35S-radiolabelled EBs and
immunoprecipitated Tarp at 10 min post infection. Radiolabeled Tarp, but not the outer
membrane protein MOMP, was degraded in HeLa cells harboring mature inclusions but not
in uninfected HeLa cells (Figure 2C). Overall, these experiments indicate that EB-associated
effectors, like the early inclusion membrane proteins described above, are subject to
degradation in a manner that correlates with the presence of CPAF.
A cell-permeable CPAF-specific inhibitory peptide prevents CPAF cleavage of host and
Chlamydia substrates
Because the lack of a system for genetic manipulation of Chlamydiae precludes the
generation of CPAF-deficient mutants or the mutation of CPAF cleavage sites in effectors, it
is difficult to directly test the functional consequence of these proteolytic events. However,
recent structural information on CPAF (Huang et al., 2008) provided the basis for the design
of a CPAF-specific inhibitory peptide (SLFYSPMVPHFWAELRNHYATSGLK) that
occludes the active site of the mature enzyme. This CPAF peptide258–283 is removed during
auto-catalytic activation of the zymogen. As a control, we synthesized a scrambled version
of the peptide. To facilitate delivery and uptake into mammalian cells we included an N-
terminal nine-Arg tail on both peptides (Stewart et al., 2008). We tested the efficiency of the
poly-Arg-tagged CPAF inhibitory peptide in vitro using an HPLC-based enzyme assay that
measures the cleavage of an Abz-tagged Vimentin derived peptide (Abz-VRLRSSVPGV).
The “anti-CPAF peptide” blocked CPAF-mediated proteolysis with ~100 fold higher
efficiency than lactacystin, the only known inhibitor of CPAF (Figure 2D). The anti-CPAF
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peptide, but not the scrambled control peptide, also inhibited cleavage of GST-tagged
chlamydial substrates and GST-Vimentin in vitro (Figure 2E and data not shown).
Importantly, the anti-CPAF peptide inhibited cleavage of Vimentin and Puma within
infected epithelial cells (Figure 2F), indicating that mammalian cells efficiently internalize
the peptide and that CPAF activity can be inhibited within live, infected cells. Moreover, the
CPAF inhibitory peptide did not induce any obvious toxicity or alter proteasome function in
uninfected cells (data not shown).
Next, we tested if this inhibitory peptide could reverse Tarp degradation upon secondary
infections. Indeed, anti-CPAF peptide restored the accumulation of Tyr-phosphorylated
proteins at EB attachment sites on pre-infected cells (Figure 2B) and partially blocked the
degradation of Tarp in pulse-chase experiments (Figure 2C), suggesting that Tarp may be a
target for other host or bacterial proteases. Overall, these observations strongly suggest that
early Chlamydia effectors are in vivo targets of CPAF and that a CPAF-specific inhibitory
peptide can efficiently inhibit CPAF activity both in vitro and in vivo.
We postulated that CPAF-mediated degradation of effectors secreted by EBs during
invasion may protect pre-infected cell against superinfection. To test whether infected cells
are refractory to re-infection, we quantified the number of EBs internalized by uninfected
cells and pre-infected cells. We observed a significant decrease in the number of newly
internalized EBs in cells that contains a mature inclusion compared to uninfected cells
(Figure 2G). This resistance to re-infection is partially mediated by CPAF, as treatment of
pre-infected cells with anti-CPAF peptides increased EB entry (Figure 2H).
CPAF activity is required for Chlamydia replication and integrity of the inclusion
While CPAF has well-established functions in the down-regulation of immune responses,
pro-apoptotic factors, and the processing of cytoskeletal proteins (Zhong, 2009), the role that
these proteolytic events play in bacterial replication and intracellular survival is unknown.
We treated Chlamydia-infected cells with anti-CPAF peptide and determined that peptide
treatment significantly lowered yields of EBs and stunted inclusion growth (Figure 3A,
Figure S3A–B). To assess the specificity of this peptide, we tested the effect of anti-CPAF
peptide on HeLa cells infected with C. muridarum and C. caviae, two chlamydial species
that display varying degrees of CPAF sequence conservation (Figure S3C). Consistent with
the high conservation between C. trachomatis and C. muridarum CPAFs, the anti-CPAF
peptide prevented cleavage of substrates by C. muridarum CPAF (Figure S3D) and blocked
C. muridarum replication (Figure S3E). In contrast, and the divergent C. caviae CPAF was
not sensitive to the anti-CPAF peptide in vitro or in vivo (Figure S3D, F).
Next, we assessed the mechanism underlying the inhibition of Chlamydia replication by
performing a microscopic analysis of infected cells treated with anti-CPAF peptide.
Prolonged inhibition of CPAF (>8 h) with the anti-CPAF peptide, but not the scrambled
control peptide, led to the collapse of the inclusion with the inclusion membrane markers
localizing to perinuclear aggregates and dispersed bacteria (Figure 3B, Figure S4I). Analysis
of these cells by transmission electron microscopy confirmed the loss of inclusion integrity
and disruption of the inclusion membrane with intact Chlamydia freely residing in the
cytoplasm (Figure 3C). Accordingly, we observed a loss of vimentin re-organization around
the inclusion (Figure 3D), which has been previously linked to inclusion stability (Kumar
and Valdivia, 2008). Consistent with the presence of intact bacteria in the cytoplasm, we
also observed enhanced secretion of IL-8 (Figure 3E). Hence, we conclude that CPAF
functions to maintain inclusion integrity during infection.
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Inhibition of CPAF induces caspase-1-dependent cell death
In addition to limiting inclusion growth, treatment with anti-CPAF peptide led to a marked
increase in the number of infected epithelial cells with condensed nuclei (Figure 4A, Figure
S4A–B). This effect is specific to CPAF, as the anti-CPAF peptide did not lead to host cell
death in C. caviae-infected cells (Figure S4E–F). Cell death occurred after 20 hpi (Figure
4A), which coincides with the translocation of CPAF into the host cytoplasm and was
observed in several non-myeloid cell lines (Figure S4C–D). Besides resulting in a ruptured
inclusion and cell death, inhibiting CPAF also led to the formation of multiple inclusions
and small inclusions (Figure S4H). Given that Chlamydia-infected cells are highly resistant
to intrinsic and extrinsic apoptotic stimuli (Greene et al., 2004) and that pro-apoptotic BH3-
only proteins are CPAF targets (Paschen et al., 2008; Pirbhai et al., 2006), we hypothesized
that CPAF inhibition led to the onset of apoptosis in infected cells. To test this, we labeled
infected cells with propidium iodide and Annexin V to monitor cell viability and the loss of
plasma membrane symmetry - a hallmark of apoptosis (Vermes et al., 1995). Chlamydia-
infected cells treated with anti-CPAF peptide did not stain with Annexin V, indicating that
the cell death is unlikely the result of classical apoptosis (Fig 4B). Consistent with this
observation, we did not detect caspase-3 cleavage, another feature of apoptotic cell death
(Figure 4C) (Galluzzi et al., 2009).
Unexpectedly, the pan-caspase inhibitor ZVAD-FMK efficiently blocked the death of
infected cells treated with anti-CPAF peptide (Figure 4D). In myeloid cells, activation of
caspase-1 by infectious agents can lead to pyroptosis, a cell death pathway accompanied by
pore formation and the release of pro-inflammatory modifiers (Brennan and Cookson, 2000;
Cervantes et al., 2008; Jesenberger et al., 2000). However, it is unclear whether this process
also occurs in epithelial cells. We determined that the caspase-1 inhibitor Ac-YVAD-cmk
efficiently blocked the death of infected epithelial cells treated with anti-CPAF peptide
(Figure 5A). In addition, we observed that caspase-1 activity, as assessed with a
fluorescently labeled caspase-1 substrate (Darzynkiewicz et al., 2011), was significantly
increased during treatment with anti-CPAF peptide (Figure 5B). Next, we confirmed the role
played by caspase-1 and its upstream activator, the inflammasome adaptor protein ASC
(Martinon et al., 2002), in mediating cell death by infecting transformed mouse lung
fibroblasts (MLF) derived from caspase-1 (ICE−/−) and ASC (Pycard−/−) knockout mice
with C. trachomatis and C. muridarum. These MLF, unlike their wild-type counterparts,
were resistant to host cell death in response to treatment with anti-CPAF peptide, indicating
that inflammasome-dependent activation of caspase-1 is required for cell death (Figure 5C,
Figure S4G). Interestingly, pharmacological or genetic inhibition of caspase-1 did not rescue
bacterial replication (Figure 5D, Figure S3E). Overall, these findings indicate that CPAF
plays at least two distinct roles in promoting chlamydial replication: mediating inclusion
stability and suppressing caspase-1 dependent cell death.
DISCUSSION
Chlamydia effector proteins, in a life-cycle stage-dependent manner, control bacterial entry,
establishment of a replicative vacuole, modulation of innate immune responses and
ultimately, exit from the host cell (Valdivia, 2008). The deployment of such a vast arsenal of
bacterial proteins into the mammalian cytoplasm presents two challenges for Chlamydia: 1)
how to limit the detection of these microbe-derived proteins by innate immune surveillance
pathways and 2) how to control the function of these proteins after they leave the confines of
the bacterial cell. Here we present evidence that CPAF, a chlamydial protease that
modulates multiple host functions required for innate and adaptive immunity (Zhong, 2009),
also cleaves a subset of effector proteins that are translocated early during infection. The
concept of a “meta” effector, one that regulates the function of others, was proposed for the
Legionella E3 ubiquitin ligase LubX, which ubiquitinates the effector SidH and targets it for
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degradation (Kubori, 2010). Our data suggests that CPAF serves a similar function by
directly cleaving a subset of secreted effectors and inclusion membrane proteins.
Because CPAF is translocated into the cytoplasm starting at 16 h post-infection (Shaw et al.,
2002), the inclusion membrane proteins we identified as CPAF-substrates are unlikely to be
cleaved until the middle stage of the infectious cycle. This is consistent with the observation
that the steady-state levels of Ct005, IncC and IncD do not decrease until later in infection
(Figure 1D). CPAF cleavage of Incs during mid cycle may be less efficient due to Inc-
modification or formation of Inc complexes that mask CPAF recognition sites. In addition,
substrate specific features (e.g. secondary or tertiary structure) may influence the efficiency
of CPAF-mediated processing. Among the 42 putative Inc proteins (Li et al., 2008) tested,
only four were identified as CPAF substrates (Figure 1), and three of these are predicted to
be expressed within the first 3 h of infection (Belland et al., 2003). Notably, not all Inc
proteins were targets of degradation, suggesting that CPAF strategically removes a subset of
Inc proteins rather than achieving a wholesale remodeling of the inclusion membrane. Inc
proteins are predicted to perform multiple functions including protection from apoptosis
(Verbeke et al., 2006), sequestration of signaling proteins (Mital et al., 2010), and re-routing
of membrane transport (Rzomp et al., 2006). We postulate that factors required early in the
biogenesis of the inclusion may not be necessary for – or may even be detrimental to –
optimal inclusion expansion later in the infectious cycle. As such, cleavage of these early
Inc proteins may be essential to the chlamydial life cycle. It is also possible that CPAF
cleavage of Inc-proteins may limit their detection by microbial pattern recognition receptors
or their processing and display by MHC class I molecules (Roan and Starnbach, 2008).
Given CPAF degradation of transcription factors required for MHC-I and MHC-II
expression (Zhong et al., 2001), cleavage of Inc proteins could further reduce the possibility
of these proteins being presented as antigens.
Two chlamydial CPAF targets (Tarp and Ct694) are translocated during EB attachment. One
condition under which EB effectors would encounter CPAF in the host cytoplasm is if an
EB where to infect a cell that already had an established inclusion. In such a scenario, CPAF
would play a role in preventing the establishment of secondary inclusions that may impair
development of the primary inclusion. Consistent with this, Tarp translocated by EBs into
cells with established inclusions is rapidly degraded (Figure 2). This degradation is partially
blocked upon delivery of a peptide-based CPAF inhibitor, indicating that Tarp is a true
target of CPAF-mediated degradation. Accordingly, EBs are blocked from entering a cell
that contains a mature inclusion, but this is reversed when CPAF activity is inhibited.
Collectively, CPAF may therefore mediate resistance to superinfection by degrading
secreted effectors involved in invasion and early inclusion biogenesis.
CPAF-specific inhibitors revealed that this protease plays an essential role in chlamydial
development and replication (Figure 3, Figure S4–5). Inclusion growth was stunted
concomitantly with a drop in the generation of infectious progeny and marked increase in
toxicity to the infected cell (Figure 3–4). The most striking effect of anti-CPAF peptide was
the loss of inclusion integrity in treated cells. Whether this is the consequence of a lack of
Inc protein turnover or processing of intermediate filaments at the inclusion membrane is
unclear. Regardless of the sequence of events leading to inclusion membrane dismantling, it
is apparent that this protease plays an essential role in maintaining the integrity of the
pathogenic vacuole.
CPAF is predicted to both prevent (Pirbhai et al., 2006) and promote (Paschen et al., 2008)
cell death depending on the stage of infection. The pro-survival mechanism of CPAF may
include the degradation of pro-apoptotic proteins, and indeed, we found that anti-CPAF
peptide blocked the cleavage of Puma (Figure 2C). However, Chlamydia-infected cells
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treated with anti-CPAF peptide initiated a cell death program that did not resemble classical
apoptosis. Instead, we found that death of infected epithelial cells upon inhibition of CPAF
activity was dependent on caspase-1 and that anti-CPAF inhibitors led to an early activation
of caspase-1 (Figure 3, 5). In myeloid cells, caspase-1 dependent cell death – also termed
pyroptosis – results in rapid plasma membrane rupture and release of pro-inflammatory
cytokines such as IL-1β and IL-18 (Bergsbaken et al., 2009). Pore formation in the plasma
membrane disrupts ionic gradients, which increases the osmotic pressure leading to swelling
and lysis. Normally, caspase-1-mediated cell death aids in the clearance of infections
(Bergsbaken and Cookson, 2007; Brennan and Cookson, 2000; Sansonetti et al., 2000).
Recently, it has been reported that Chlamydia infection activates caspase-1 in epithelial cells
late during infection and is required for optimal chlamydial growth (Abdul-Sater et al.,
2009; Lu et al., 2000). Potentially, the dependence of chlamydial growth on caspase-1 is a
consequence of enhanced lipid biosynthesis that occurs upon activation of low levels of
caspase-1 (Gurcel et al., 2006). However, upon inhibition of CPAF, caspase-1 activation
occurs much earlier and with greater magnitude, most likely as a result of an overwhelming
response to bacterial products in the cytoplasm. We predict that this premature activation of
caspase-1 triggers an irreversible cell death program in Chlamydia-infected non-myeloid
cells, as has been recently proposed in Salmonella that resides in the cytoplasm of infected
colonic epithelial cells (Knodler et al., 2010). It is also possible that CPAF plays a more
direct role in suppressing inflammasome formation as has been demonstrated for the
Yersinia effectors YopE and YopT (Schotte et al., 2004) and the poxvirus pyrin-domain
protein M13L (Johnston et al., 2005).
Overall, these studies establish that CPAF is an essential Chlamydia virulence factor with an
important role in maintaining the integrity of the inclusion and preventing the premature
death of its host cell in a single-cell, autonomous tissue culture model of infection (Figure
6). Furthermore, CPAF plays a previously unappreciated role in the turnover of other
effectors to aid in the remodeling of the inclusion and to limit secondary infections.
Consistent with its obligate intracellular lifestyle and its small genome, it is not surprising
that Chlamydia has become adept at multi-tasking by expressing regulatory effectors with
multiple functions, like CPAF. Thus, CPAF emerges as a central virulence protein and an
attractive target for the design of specific protease inhibitors for therapeutic intervention.
EXPERIMENTAL PROCEDURES
Expression constructs and proteolysis screen
C. trachomatis ORFs cloned into the yeast expression vector pSDY8 (C-terminal GFP tag)
(Sisko et al., 2006) or the E. coli expression vector pGEX-4T-1 vector (GE Healthcare) are
listed in Table S1. Hexahistidine-tagged CPAF (pET30b) was purified as previously
described (Huang et al., 2008). For in vitro cleavage assays, Chlamydia proteins fused to
EGFP or GST were expressed in yeast and E. coli respectively. Yeast lysates or purified
GST-tagged were incubated with cytosols from uninfected or LGV-L2 infected (40 h) HeLa
cells for 30 min at 37°C. Processed chlamydial proteins were detected by immunoblot
analysis with anti-GFP antibodies or Coomassie Blue staining.
Cell culture and Chlamydia infections
MLFs from Pycard−/−, ICE−/− and WT mice were isolated as previously described (van
Deventer et al., 2008). Ex vivo lungs were minced, incubated with 1 mg/ml collagenase A
and 20μg/ml DNAse I in RPMI supplemented with 2% fetal calf serum (FBS) for 45 min at
37°C. Digested lungs were filtered, washed and red blood cells were lysed in NH4CaK
buffer. Cultured MLFs were immortalized by lentiviral mediated transduction of T-antigen
and human telomerase as previously described (O’Hayer and Counter, 2006). HeLa cells
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(ATCC) and MLFs were maintained in DMEM supplemented with 10% FBS (CellGro
Mediatech Inc). C. trachomatis LGV-L2 434/Bu was propagated in HeLa cells as previously
described (Caldwell et al., 1981). EBs were added to HeLa cells at the indicated MOIs and
infections were synchronized by centrifugation at 300×g for 30 min at 4ºC. C. muridarum
Nigg and C. caviae stocks were kind gifts from Roger Rank (University of Arkansas).
Generation of antibodies and immunodetection protocols
Rabbits were immunized with recombinant GST fusions to Ct005, IncC, IncD, Tarp (Ted
Hackstadt, RML/NIH) and hexahistidine-tagged CPAF (J. Chai, Institute of Biological
Sciences, Beijing) produced in E. coli BL21-DE3 (Stratagene) and purified by affinity
chromatography. IgG antibodies were purified with Protein A-coated Sepharose beads (GE
Healthcare). Membrane-associated chlamydial proteins were harvested from infected HeLa
by ultracentrifugation of whole cell lysates on an Optiprep (Sigma) discontinuous density
gradient (25, 20, 17.5, 15, 12.5, 10%) and assessing the fractionation of IncA and IncG
positive membranes by immunoblot analysis. To assess CPAF cleavage of membrane
proteins and EB proteins, purified membranes and soluble EB protein lysate were incubated
with 6xHis-CPAF at 37°C for 20 min, and resulting product analyzed by immunoblots with
specific antibodies.
Generation of Inhibitory peptide and CPAF cleavage assays
The anti-CPAF peptide (SLFYSPMVPHFWAELRNHYATSGLKRRRRRRRRR) and
scrambled control (NFALSHFRLPLSTYKEMPYVSHWAGRRRRRRRRR) peptide were
synthesized by solid-phase peptide synthesis by the FMOC t-Boc method. Peptides were
purified to homogeneity by reverse-phase HPLC, and confirmed by mass spectrometry.
Scaled up production of peptides were performed by Eton Biosciences (Durham, NC) and
purified by HPLC. IC50 values were determined by assessing cleavage inhibition of an Abz-
tagged Vimentin peptide VRLRSSVPGV-NH2. His-CPAF was pre-incubated with 10μM
Lactacystin (EMD), solvent control (DMSO), ACP or CP at 37ºC for 30 min. Cleavage
products were assessed by HPL analysis. To assess CPAF-dependent cleavage during
infection, 1.2×106 HeLa cells were grown in 6-well plates and infected with LGV-L2 at an
MOI of 1, treated with anti-CPAF or control peptide at 12 hpi and harvested at 30 hpi.
Immunofluorescence microscopy (IF)
A detailed list of antibodies used in this study is available in supplemental data (Table S3).
For routine indirect immunofluorescence, 0.2×106 HeLa cells were grown on glass
coverslips and infected at the indicated MOI. Cells were fixed with cold 3% formaldehyde
in phosphate-buffered saline (PBS), permeabilized with 0.1% Triton X-100, blocked in 2%
bovine serum albumin (BSA) and incubated with the specified primary antibodies in
2%BSA in PBS and fluorophore-conjugated anti-rabbit or anti-mouse goat IgG (Molecular
Probes). Host and bacterial DNA were stained with 1μM Hoechst in PBS (Invitrogen).
Infected cells were imaged with a Zeiss Axioscope epifluorescence microscope and
Axiovision v3.0 software or a Leica TCS SL confocal microscope and processed with Leica
software. For transmission electron microscopy (TEM), HeLa cells grown on thermanox
(Electron Microscopy Services) coverslips were infected with LGV-L2 and treated with
anti-CPAF peptide as described above, fixed with 0.05% malachite green/2.5%
gluteraldehyde, postfixed with 0.8% osmium tetroxide and 1% tannic acid and 1% uranyl
acetate. Following dehydration with ethanol of samples, sections were post-stained and
imaged with a Tecnai G12 Twin electron microscope (FEI).
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Radiolabeling and secondary infections
HeLa cells were infected with C. trachomatis for 18 h and labeled with 300μCi S35 cysteine/
methionine (Perkin Elmer) in the presence of 40μg/ml cyclohexamide (Sigma) for an
additional 22 h. EB seed was harvested following gentle sonication and stored at −80°C in
SPG buffer (0.25M sucrose, 10 mM sodium phosphate, 5 mM L-glutamic acid). Uninfected
or HeLa cells that had been pre-infected for 30 h were infected with unlabeled or S35-
labeled LGV-L2 seed at an MOI of 50. Cells were washed extensively with trypsin, and
harvested at 10 min post the secondary infection in lysis buffer (20 mM Tris, 150 mM NaCl,
1% Tx100, 2 mM PMSF, 2 mM MG132, 10 mM ALLN, protease inhibitor cocktail
(Roche)). Tarp and MOMP were immunoprecipitated using anti-TARP and anti-MOMP
polyclonal antisera and Protein A-coated Sepharose beads (GE Healthcare) and detected in a
Typhoon9410 Variable Image PhosphorImager (Amersham Biosciences), and quantified
using ImageQuant 5.1TL (GE Healthcare). To test the effect of inhibitory peptide, cells were
treated with 12μM peptides for the duration of the secondary infections. To distinguish
intracellular from extracellular EBs, cells were infected with CellTracker (Invitrogen)-
labeled EBs for 30 min, fixed without premeabilization and extracellular EBs were
immunostained with an anti-L2 antisera.
Cytokine, apoptosis, and caspase-1 activation assays
HeLa cells were infected with C. trachomatis LGV-L2 at an MOI of 1. At 3 hpi, cells were
treated with 40μM Z-VAD-FMK (Promega) or 400μM Ac-YVAD-cmk (Enzo Life
Sciences). At 12 hpi, cells were treated with 12.5μM of anti-CPAF peptide or control
peptide. IL-8 secretion into the media was determined with a Human IL-8 ELISA kit
(BioLegend) as recommended by the manufacturer. Apoptotic cells were identified with an
AnnexinV-FLOUS Staining Kit (Roche) and activation of caspase-1 was determined by
labeling active caspase-1 with a Carboxyfluorescein FLICA Detection Kit
(Immunochemistry) and analyzed in a FACScanner (BD).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. CPAF cleaves a subset of early chlamydial effectors
(A) Recombinant Chlamydia ORFs (n=309) were tested for sensitivity to host – and
bacterial – derived proteases.
(B) Recombinant CPAF cleaved chlamydial substrates in a cell-free proteolysis assay.
Approximately 40 ng purified his-tagged CPAF was incubated with 48μg GST-tagged
Chlamydia proteins at 37°C for 20 min with increasing concentrations of lactacystin.
Cleavage products were run on an SDS PAGE gel and visualized with Coomassie.
(C) Schematic summary of bacterial targets of CPAF. CPAF specifically cleaves chlamydial
effectors translocated during EB entry and early inclusion biogenesis, with the exception of
Ct813, which is transcribed starting at 8hpi.
(D) The steady state levels of the Inc CPAF substrates decrease at late stages of infection.
Membranes from Chlamydia-infected HeLa cells were harvested at 0, 24, 36 and 48 hpi,
purified, and the abundance of the chlamydial proteins Ct005, IncC and IncD monitored
with specific antibodies. IncG and MOMP are an inclusion membrane protein and an outer
membrane protein, respectively, that were determined not to be protease sensitive. Na/K
ATPase serves as host membrane loading control.
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Figure 2. A cell-permeable CPAF-specific inhibitory peptide blocks cleavage of Chlamydia
effectors during infection
(A–C) Tarp translocated by EBs is a target of CPAF-mediated degradation. Uninfected
HeLa cells and HeLa cells pre-infected with L2 for 30 h were treated with a cell permeable
poly-arginine tagged CPAF inhibitory (“anti-CPAF”) peptide and infected with EBs for 10
min. Tarp translocation was indirectly visualized with an anti-phosphotyrosine antibody (A)
and quantified in 50 separate cells (B). Error bars represent +/− St. error. The stability of
newly translocated Tarp was assessed by infecting cells as in (A) but with S35-labeled EBs,
followed by sequential immunoprecipitation of Tarp and MOMP and PhosphoImager
analysis of precipitated material (C). Note CPAF-dependent Tarp degradation in pre-
infected HeLa cells. Error bars represent +/− SD.
(D) Inhibition of CPAF activity by inhibitory peptide. IC50 values were assessed by
monitoring the cleavage of a synthetic fluorophore-tagged, vimentin-derived substrate by
HPLC. Assays were performed in the presence of increasing amount of inhibitors. The IC50
values of the anti-CPAF peptide and Lactacystin were 0.05μM +/− 0.007 sd and 10μM +/−
2.3 sd, respectively.
(E–F) Anti CPAF peptide, but not a scrambled control peptide, broadly inhibits degradation
of CPAF substrates in vitro and in vivo. CPAF cleavage of GST-chlamydial substrates were
performed as in Fig. 1B but in the presence of anti-CPAF or scrambled control peptide (E).
For in vivo inhibition effects on Chlamydia (L2), infected HeLa cells were treated with
peptide at 12 hpi, and harvested at 30 hpi (F). Vimentin and Puma cleavage is inhibited in
infected cells treated with anti-CPAF peptide.
(G–H) CPAF restricts EB entry into pre-infected cells. Cells were infected as in (A), except
that the secondary infections (30 min) were performed with fluorescently-labeled EBs
(green) and infected cells were not permeabilized. Extracellular EBs were distinguished
from intracellular EBs (green) based on their immunoreactivity to anti-L2 antibodies (red).
Extracellular bacteria appear yellow (G). Also note clustering of internalized bacteria at a
perinuclear site. Number of internalized EBs was quantified per cell (H). Representative of
two experiments performed in duplicate (n=40 cells). Error bars represent +/− St. error.
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Figure 3. CPAF is required for chlamydial replication and inclusion maintenance
(A) Anti-CPAF peptide blocks the generation of Chlamydia infectious particles. L2-infected
HeLa cells were treated at 12 hpi with increasing concentration of peptide. EBs were
harvested at 30 hpi and Inclusion forming units (IFU) were quantified. Error bars represent
+/− St. error.
(B–D) CPAF activity is required to maintain inclusion integrity. DNA was stained with
Hoechst (blue). Inclusion integrity was assessed by immuno-localization of the inclusion
membrane marker IncA (red) and Chlamydia (green) (B) and by transmission electron
microscopy (C). Note collapse of IncA-positive membranes and loss of inclusion integrity
with bacteria in the cytoplasm (arrows) of infected cells lacking CPAF activity (right
panels). (D) Vimentin-positive inclusions were identified by IF of infected cells fixed 24 hpi
subsequent to treatment with control and inhibitory peptide at 12 hpi. Error bars represent +/
− St. error.
(E) Inhibition of CPAF activity leads to activation of inflammatory cytokines. Levels of
IL-8 in supernatants from Chlamydia infected cells treated with inhibitory peptide as in (B–
D) were determined by ELISA at 24 hpi. Error bars represent +/− St. error.
Jorgensen et al. Page 16













Figure 4. Inhibition of CPAF activity induces non-apoptotic death of host cells
(A) Inhibiting CPAF activity induces host cell death. Inhibitory peptide was added to
infected HeLa cells 12 hpi and the percentage of infected cells with condensed nuclei was
quantified at the indicated times. Error bars represent +/− St. error.
(B–C) Inhibition of CPAF activity does not induce apoptosis. Infected cells were treated
with inhibitory peptide and the percentage of AnnexinV-FITC positive cells among
propidium iodide (PI) negative cells was determined by flow cytometry (B). In parallel
samples, cleavage of caspase-3, a hallmark of apoptosome activation, was monitored by
immunoblot analysis. Actin and MOMP are host and bacterial loading controls, respectively.
Treatment with staurosporine (2 μM) and the pan-caspase inhibitor Ac-ZVAD-fmk were
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used as controls for the induction of apoptosis and caspase activity, respectively. Error bars
represent +/− St. error.
(D) The pan-caspase inhibitor Ac-ZVAD-FMK blocks death of Chlamydia-infected
epithelial cells. Infected HeLa cells were treated as in (A) in the presence or absence of Ac-
ZVAD-fmk. Cell toxicity was determined by flow cytometry of PI-stained cells. PI staining
was not seen in cells pre-treated with Ac-ZVAD-fmk or the scrambled control peptide. Error
bars represent +/− St. error.
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Figure 5. Death of Chlamydia infected cells treated with CPAF inhibitory peptide is dependent
on caspase-1
(A) Caspase-1 inhibitors block Chlamydia-mediated cell death. Infected HeLa cells were
treated with inhibitory peptide at 12 hpi, fixed at 24 hpi, and the percentage of cells with
condensed nuclei was quantified. Ac-YVAD-cmk was added at 2 hpi. Error bars represent +/
− St. error.
(B) Caspase-1 activation is enhanced during infection when CPAF is inhibited. Infected
cells were labeled with a cell-permeable fluorescent substrate of caspase-1 and treated with
anti-CPAF peptide, and caspase-1 activity at 28 h post infection was monitored by flow
cytometry.
(C) Caspase-1 and ASC are required for Chlamydia-mediated host cell death. Chlamydia-
infected lung fibroblasts derived from caspase-1 (ICE−/−) and ASC adaptor (ASC−/−)
knockout mice were resistant to cell death induced by anti-CPAF peptide. Error bars
represent +/− St. error.
(D) CPAF is required for chlamydial replication independently of its role in suppressing
caspase-1 mediated cell death. Chlamydia replication and generation of IFUs in MLFs was
assessed as in Fig 3. Note dose-dependent loss in IFU yields in all MLF lines. Error bars
represent +/− St. error.
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Figure 6. CPAF mediates resistance to re-infection, inclusion integrity and protection from
caspase-1-mediated cell death
CPAF reorganizes intermediate filaments at the inclusion periphery to promote inclusion
stability (Kumar and Valdivia, 2008) and mediates protection from re-infection by targeting
effectors translocated during invasion and early inclusion biogenesis. Inhibition of CPAF
activity leads to a loss of protection from re-infection. In addition, CPAF activity is required
to maintain inclusion membrane integrity, dampen the secretion of pro-inflammatory
cytokines, and prevent inflammasome-dependent activation of caspase-1-dependent cell
death.
Jorgensen et al. Page 20
Cell Host Microbe. Author manuscript; available in PMC 2012 July 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
